Fusosome compositions and methods are described herein.

An object of the present invention is to provide a compound or a salt thereof constituting lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids, and to provide lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids. According to an aspect of the present invention, a compound represented by Formula (1) or a salt thereof is provided.

##STR00001##

In the formula, X represents NR.sup.1 or O, R represents a hydrogen atom, a hydrocarbon group, or the like, R.sup.2 and R.sup.3 each independently represent a hydrogen atom, a hydrocarbon group, or the like, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, and R.sup.12 each independently represent a hydrogen atom or an alkyl group, groups in any one or more pairs among R.sup.4 and R.sup.5, R.sup.10 and R.sup.5, R.sup.5 and R.sup.12, R.sup.4 and R.sup.6, R.sup.5 and R.sup.6, R.sup.6 and R.sup.7, R.sup.6 and R.sup.10, R.sup.12 and R.sup.7, and R.sup.7 and R.sup.8 may be linked to each other to form a 4- to 7-membered ring which may contain an O atom, a, b, c, and d are each independently represent an integer of 0 to 3, a+b is equal to or greater than 1, and c+d is equal to or greater than 1.

The present disclosure relates to a drug combination for treating non-small cell lung cancer, in particular to uses of ergosterol combined with gefitinib, and belongs to the technical field of biomedicine. In the present disclosure, the mechanism of action that ergosterol (ERG) combined with gefitinib (GEF) induces apoptosis of non-small cell lung cancer (NSCLC) cells is firstly studied; then an RGG cyclic peptide/R8 peptide modified ERG combined with GEF active drug-loaded targeted liposome delivery system (RGD/R8-ERG/GEF-LIP) is constructed; and the RGD/R8-ERG/GEF-LIP is prepared into a freeze-dried powder to improve stability, quality evaluation and preliminary evaluation of in vitro anti-lung cancer effects are conducted, and a nude mouse lung cancer xenograft model is established for conducting preliminary pharmacodynamic research and in vivo targeting research.

The present invention provides a biomolecular composite which is a ghost cell which has been emptied of all or substantially all of the cytosolic contents of the cell including the nucleus and nuclear contents, preferably further having been fused with exogenous amphipathic molecules, wherein said composite has a hydrodynamic diameter of less than 6 m. The biomolecular composite may contain a cargo molecule and be capable of targeting a cell or tissue. Also provided are methods of preparing ghost cells, methods of preparing biomolecular composites and methods for their use.

The present disclosure relates to a method of loading a toll like receptor (TLR)7/8 agonist into a liposome using remote loading and a kit of parts suitable for the loading of a TLR7/8 agonist into a liposome by said method. The present disclosure further relates to a liposome comprising a salt of a TLR7/8 agonist in the liposome interior and to the use of said liposome for stimulation of an immune response and/or treatment of a clinical condition. Finally, the present disclosure relates to a TLR7/8 agonist which is suitable for being remotely loaded into a liposome.

The present invention provides a novel liposome composition containing eribulin or its pharmacologically permissible salt, and its method of manufacture.

Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.

A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.

The disclosure generally relates to lipid nanodiscs, in particular to lipid nanodiscs formed from polymers. A lipid nanodisc according to the disclosure includes a lipid bilayer having a first hydrophilic face and a second hydrophilic face opposing the first hydrophilic face, and a hydrophobic edge between the opposing hydrophilic faces, and a polymer encircling the hydrophobic edge of the lipid bilayer. The polymer includes a first monomeric unit having a pendant hydrophobic group and a second monomeric unit having a backbone hydrophilic group. Methods of making and characterizing the lipid nanodiscs are also disclosed.

Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.